What To Expect For Ardelyx In The Coming Month (NASDAQ:ARDX)
seekingalpha.com
finance
2022-10-18 10:09:35

Md Saiful Islam Khan/iStock via Getty Images Ardelyx (NASDAQ:ARDX) is a small biopharmaceutical with a market cap around $210 million. The company is repurposing its first commercial product, IBSRELA (tenapanor), indicated for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in the U.S. and Canada, as a novel product candidate to control serum phosphorus in adult patients with chronic kidney disease (or CKD) Stage 5 (receiving hemodialysis). If approved, it will be sold under the brand XPHOZAH.
